Adjunctive Celecoxib in Childhood-onset OCD Study

Phase 2 Unknown 80 enrolled University of British Columbia BC Children's Hospital Research Institute · collab Obsessive Compulsive Foundation · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, controlled, single-centre phase II superiority trial to determine the efficacy of 12 weeks of celecoxib (50 mg or 100 mg orally twice daily, dosed based on weight) compared to placebo as an adjunct to treatment-as-usual in children and youth with moderate-to-severe obsessive-compulsive disorder.

Timeline

Start: 2021-06-01
Primary completion: 2023-06
Completion: 2023-06

Publications

Westwell-Roper C, Best JR, Elbe D, MacFadden M, Baer S, Tucker L, Au A, Naqqash Z, Lin B, Lu C, Stewart SE. Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive-compulsive disorder: protocol for a single-site randomised quadruple-blind phase II study. BMJ Open. 2022 Jan 31;12(1):e054296. doi: 10.1136/bmjopen-2021-054296.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Celecoxib	Other / unclassified	50 mg	Oral
Subject	Celecoxib	Other / unclassified	100 mg	Oral

Adjunctive Celecoxib in Childhood-onset OCD Study

Summary

Timeline

Publications

Drugs

Indications